To achieve a better understanding of the molecular determinants of the bortezomib response we re-analyzed transcriptional and clinical data of the REMoDL-B trial and described for the first-time the aberrant expression and prognostic significance of CDCA2 in DLBCL. This evidence concerns the gene CDCA2 and diffuse large B-cell lymphoma.